Xiao Haipeng, He Qianjin, Hu Yang, Li Chang, Tian Han, Chen Feng, Song Wenchong
Department of General Surgery, Huanggang Central Hospital of Yangtze University, Huanggang, China.
Department of Hepatobiliary Surgery/Hernia Surgical Ward, Huanggang Central Hospital of Yangtze University, No.6 Qi 'an Avenue, Huangzhou District, Huanggang, 438000 Hubei China.
3 Biotech. 2025 Jan;15(1):32. doi: 10.1007/s13205-024-04166-5. Epub 2025 Jan 4.
Gastric cancer is one of the major cancers with high cancer mortality and shows significant heterogeneity. The development of precise prognostic models is crucial for advancing treatment strategies. Recognizing the pivotal role of DNA damage in tumor progression, we conducted a consensus clustering analysis of DNA damage-related genes to categorize gastric cancer patients from the TCGA clinical cohort into distinct subtypes. Prognostic models were then constructed utilizing machine learning algorithms following Cox regression with differentially expressed genes. Validation was performed using the GSE gastric cancer cohort. Additionally, we investigated other characteristic responses of patients through gene mapping and drug sensitivity analysis. This study 12 differentially prognostic signature genes between the 2 DNA damage subtypes identified were used to calculate risk scores for the patients. This score predicts the prognosis of patients with gastric cancer and their overall survival time. Higher risk scores mean less drug sensitivity, lower survival, and possibly a poorer response to immunotherapy. Our findings provide the basis for future studies targeting DNA damage and its immune microenvironment to improve prognosis and response to immunotherapy.
胃癌是癌症死亡率较高的主要癌症之一,具有显著的异质性。精确预后模型的开发对于推进治疗策略至关重要。认识到DNA损伤在肿瘤进展中的关键作用,我们对DNA损伤相关基因进行了一致性聚类分析,以将来自TCGA临床队列的胃癌患者分为不同的亚型。然后,利用机器学习算法,基于Cox回归和差异表达基因构建预后模型。使用GSE胃癌队列进行验证。此外,我们通过基因图谱和药物敏感性分析研究了患者的其他特征性反应。本研究中,所确定的2种DNA损伤亚型之间的12个差异预后特征基因用于计算患者的风险评分。该评分可预测胃癌患者的预后及其总生存时间。较高的风险评分意味着较低的药物敏感性、较短的生存期以及可能对免疫治疗的反应较差。我们的研究结果为未来针对DNA损伤及其免疫微环境的研究提供了基础,以改善预后和免疫治疗反应。